LIVE: Reuters NEXT Newsmaker with EMA Executive Director Emer Cooke
TL;DR
EMA Executive Director Emer Cooke defends Europe's life sciences sector against claims of falling behind the US and China, emphasizing new regulatory frameworks and industry engagement, while warning that US drug pricing policies threaten to delay launches and limit patient access to new medicines including weight loss pills expected by summer.
🔬 Europe's Innovation Landscape 3 insights
Defending European competitiveness
Cooke rejects narratives of European decline, citing active implementation of new pharma legislation, the Biotech Act, and Critical Medicines Act to boost innovation and competitiveness.
Regulatory modernization efforts
EMA is deploying "sandbox" regulatory approaches and platform technologies ahead of formal legislation while engaging directly with biotech clusters to connect innovators with financing.
Industry collaboration initiative
The agency recently convened 24 pharmaceutical companies to discuss leveraging Europe's strengths in data digitalization and AI to attract R&D investment.
💶 Drug Access and Pricing Pressures 3 insights
US pricing impact on launches
Cooke warns that US international reference pricing policies have contributed to a 35% drop in EU drug launches, potentially delaying access to breakthrough treatments for European patients.
Calls for unified procurement
To counter fragmented national markets, she advocates for "more Europe" through joint procurement mechanisms in the Critical Medicines Act, creating larger, more attractive markets for manufacturers.
Weight loss pill timeline
Regulatory decisions on oral GLP-1 weight loss medications from Novo Nordisk and Eli Lilly are expected by summer.
🌐 Global Regulatory Dynamics 3 insights
Continued FDA collaboration
Despite Trump administration leadership changes, EMA maintains daily contact with FDA colleagues and recently published joint AI principles while restarting staff exchange programs.
Scientific talent migration
Cooke notes anecdotal evidence of US scientists and former FDA staff relocating to European institutions amid American research funding uncertainties, positioning Europe as stable and predictable.
China engagement strategy
While acknowledging record Chinese biotech licensing deals, she admits few applications currently reach EMA despite impressive regulatory improvements in China.
⚕️ Supply Security and Shortages 2 insights
Antibiotic shortage reduction
Using new 2023 legal powers, EMA's Medicine Shortage Steering Group reduced antibiotic shortages by over 50% through proactive supply-and-demand monitoring after COVID disruptions.
Emergency preparedness limitations
Cooke acknowledges Europe likely cannot produce vaccines within six months of a new health emergency, citing the 10-12 month COVID timeline as the realistic standard even with unprecedented collaboration.
Bottom Line
Europe must adopt centralized procurement and unified market approaches to remain competitive for drug launches, as fragmented national pricing increasingly drives manufacturers to prioritize the US and China while threatening patient access.
More from Reuters
View all
LIVE: National Mall filled with teddy bears for abducted Ukrainian children
Activists placed 20,000 teddy bears on the National Mall to represent Ukrainian children abducted by Russia, with speakers warning that the true number may reach 200,000 and demanding that the return of these children be a precondition for any peace negotiations with Moscow.
LIVE: EU heads of state discuss Iran crisis and energy security
EU leaders convened to address the Iran crisis and energy security, unblocking €90 billion in aid for Ukraine while debating defense autonomy under Article 42.7 and strategies to reduce energy dependence on Russia.
LIVE: House Democratic Leader Jeffries speaks in DC
House Democratic Leader Hakeem Jeffries criticized Republicans for blocking bipartisan DHS funding to prioritize ICE deportations, condemned Trump's Iran war as strengthening adversaries while raising gas prices, and highlighted 16 months of consecutive Democratic electoral wins despite widespread voter frustration with institutions.
The Gulf energy crisis and the US-China showdown
Political economist Helen Thompson analyzes the US-Iran conflict as part of a broader Trump administration strategy to disrupt China's energy security while navigating the temporary nature of US shale independence and historical tensions between American military protection and global energy flows.